An early-stage healthcare venture fund established in 2018 with USA-based teams looks to invest in companies and teams with novel approaches in both the life sciences and Bio-IT sector.
The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Bio-IT sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow.
The firm is actively looking for companies from Seed to Series A and is focused on the US with select opportunities globally.
The firm is focused on two main investment themes:
(1) Life Sciences – The firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and immune based disease. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;
(2) Bio IT – Bio IT is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery / development (proteomics and metabolomics), and new solutions to improve the efficiency of new modalities (i.e., cell therapy manufacturing, gene therapy carries, etc.).
The firm is looking for experienced management teams with strong scientific expertise and management skills.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply